Aardvark Therapeutics, Inc. (AARD)

Aardvark Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	82.28	9.74	15.56
Short-Term Investments	0.08	0.25	0.55
Cash & Short-Term Investments	82.36	9.99	16.11
Cash Growth	411.39%	-37.98%	-
Prepaid Expenses	0.17	0.25	0.32
Other Current Assets	0.14	0.13	0.07
Total Current Assets	82.67	10.37	16.49
Property, Plant & Equipment	0.84	0.16	0.25
Other Long-Term Assets	0.23	0.01	0.01
Total Assets	83.74	10.54	16.76
Accounts Payable	0.67	1.04	0.26
Accrued Expenses	1.62	0.24	0.24
Current Portion of Leases	0.32	0.11	0.1
Total Current Liabilities	2.61	1.38	0.6
Long-Term Leases	0.55	0.05	0.16
Other Long-Term Liabilities	-	0	0.02
Total Liabilities	3.16	1.43	0.78
Additional Paid-In Capital	3.37	2.94	2.61
Retained Earnings	-49.55	-37.74	-30.53
Total Common Equity	-46.17	-34.8	-27.92
Shareholders' Equity	80.58	9.1	15.98
Total Liabilities & Equity	83.74	10.54	16.76
Total Debt	0.87	0.16	0.26
Net Cash (Debt)	81.49	9.83	15.84
Net Cash Growth	414.37%	-37.97%	-
Net Cash Per Share	20.52	2.48	4.07
Filing Date Shares Outstanding	21.38	3.97	3.89
Total Common Shares Outstanding	4.06	3.97	3.89
Working Capital	80.05	8.99	15.9
Book Value Per Share	-11.38	-8.77	-7.18
Tangible Book Value	-46.17	-34.8	-27.92
Tangible Book Value Per Share	-11.38	-8.77	-7.18

Source: S&P Capital IQ. Standard template. Financial Sources.